Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.50 |
| ▸ | MAP2K2 | P36507 | 7/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.50 |
| ▸ | ADCK1 | Q86TW2 | 1/20 | 0.50 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1978903 | 0.89 | MAP2K1 (0.46) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL1982682 | 0.89 | MAP2K1 (0.66) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL14151243 | 0.89 | MAP2K1 (0.66) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL14151925 | 0.89 | MAP2K1 (0.66) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL1979211 | 0.87 | MAP2K1 (0.45) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL392701 | 0.82 | MAP2K1 (0.61) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL12597717 | 0.81 | MAP2K1 (0.40) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL12697013 | 0.80 | MAP2K1 (0.42) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL391581 | 0.79 | MAP2K1 (0.55) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL1978944 | 0.79 | MAP2K1 (0.49) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509964-B1 | Heterocyclic sulfonamide derivatives | NOVARTIS AG (CH) | 2014-04-30 | — | — | EP | claimed |
| US-20120245209-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
| WO-2011070030-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-06-16 | — | — | WO | disclosed |
| US-20100291151-A1 | 1-METHYLPYRAZOLE MODULATORS OF SUBSTANCE P, CALCITONIN GENE-RELATED PEPTIDE, ADRENERGIC RECEPTOR, AND/OR 5-HT RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291151-A1 | 1-METHYLPYRAZOLE MODULATORS OF SUBSTANCE P, CALCITONIN GENE-RELATED PEPTIDE, ADRENERGIC RECEPTOR, AND/OR 5-HT RECEPTOR | TACR1, HTR3A, HTR3C | MAP2K1 3844/4885MAP2K2 3624/4885CHEK1 2699/4885 |
| US-20120245209-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | BRAF, NRAS, MAP3K1 | MAP2K1 103/4885MAP2K2 77/4885CHEK1 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.